Cancer is a complex disease where multiple genetic and environmental factors contribute to risk. Its onset and progression depends on the combination of a series of genetic disruptions rather than on ...

The PTEN-PI3K-AKT pathway is among the most frequently dysregulated oncogenic pathways in metastatic castration-resistant prostate cancer (mCRPC). Multiple inhibitors of this pathway are in late-phase ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window A ...

Truqap with Zytiga and ADT improved radiographic progression-free survival in patients with PTEN-deficient prostate cancer compared to placebo. The CAPitello-281 trial involved 1,012 patients, showing ...

A team of researchers from the Badalona Applied Research Group in Oncology (B·ARGO) and the Urologic Tumours Unit of the Institut Català d'Oncologia (ICO) and the Germans Trias i Pujol Research ...

A new research paper was published in Genes & Cancer on May 16, 2024, entitled, "Inhibitory effect of miR-377 on the proliferative and invasive behaviors of prostate cancer cells through the ...

Immunotherapies have been successful in treating many cancer conditions; however, not much success has yet been achieved in metastatic castrate-resistant prostate cancer (mCRPC). A study published ...

ctDNA Predicts Overall Survival in Patients With NSCLC Treated With PD-L1 Blockade or With Chemotherapy A next-generation sequencing–based cfDNA assay was used to profile 231 patients with mCRPC from ...